Puriblood Medical Co., Ltd. (TPEX:6847)

Revenue by Segment

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
High-End Blood Purification Related Medical Equipment & Animal Blood Transfusion	82.34M	110.67M	125.27M	137.44M	54.59M
High-End Blood Purification Related Medical Equipment & Animal Blood Transfusion Growth	-25.61%	-11.65%	-8.86%	151.79%	41.25%
Total	82.34M	110.67M	125.27M	137.44M	54.59M
Total Growth	-25.61%	-11.65%	-8.86%	151.79%	41.25%

Revenue by Geography

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Taiwan	63.76M	100.79M	117.54M	132.61M	51.46M
Taiwan Growth	-36.74%	-14.25%	-11.36%	157.71%	43.92%
Other	18.57M	9.88M	7.72M	4.83M	3.13M
Other Growth	88.01%	27.90%	59.82%	54.41%	1142.06%
Total	82.34M	110.67M	125.27M	137.44M	54.59M
Total Growth	-25.61%	-11.65%	-8.86%	151.79%	41.25%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jun 23, 2026

Data Sources Report a data error